2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH SUSAN HALABI
Racial Disparities in Prostate Cancer Treatment and Outcomes

VIEW ALL PROSTATE CANCER VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH MICHAEL HOFMAN
Theranostic Approaches for Advanced Prostate Cancer

VIEW ALL IMAGING: PROSTATE VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL nmCRPC VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH MATTHEW GALSKY
Combination Approaches with Immune-Checkpoint Blockade in Bladder Cancer

VIEW ALL BLADDER CANCER VIDEOS

Featured Videos

EAU 2014 - Effects of prior use of statins in a phase 3 study of intermittent versus continuous combined androgen deprivation - Session Highlights

STOCKHOLM, SWEDEN (UroToday.com) - In this trial, 918 men (median PSA of 15.9ng/ml) were randomized with inclusion criteria being: histologically confirmed prostate adenocarcinoma, cT3–cT4 M0 or M1, serum PSA > 4 ng/ml and PSA ≤ 100 ng/ml age ≤ 80 years, World Health Organization (WHO) performance status 0–2, and normal liver function not suitable for definitive treatment. On registration, they were able to collect data on statin use from 252 patients, of whom 129 did not use statins and 123 used statins. Among this subgroup of patients, 115 received continuous therapy and 137 intermittent therapy. Within the continuous arm, 49.6% of patients used statins, while among the intermittent arm, 48.2% used statins. eauAmong those who used statins, 21 died (12 from prostate cancer, 5 from CVD, 4 from other causes) and among those who did not use statins 45 died (25 from prostate cancer, 14 from CVD, 6 from other causes). They reported that for prostate cancer death, the corresponding hazard ratio was 0.44 (95% CI 0.22-0.90, p = 0.025), and for CVD death it was 0.30 (95% CI 0.11, 0.83, p = 0.020). The only factors that were associated with overall survival were metastatic status and statins use, HR=0.39 (95% CI 0.23-0.65, p = 0.0004).

In 2013, Geybels, et al. reported that prior use of statins is associated with better survival among men with newly diagnosed prostate cancer. In this retrospective sub-analysis of a phase 3 randomized clinical trial, authors were also able to show the protective effect of statin use on prostate cancer mortality. Further studies, using larger cohorts, are needed to further evaluate the effect of this medication on prostate cancer mortality.

Presented by F. Calais Da Silva, Jr.,1 F. Calais Da Silva, Sr.,1 F. Gonçalves,2 J. Kliment,3 P. Whelan,4 N. Antoniou,5 S. Pastidis,6 Y. Beduk,7 and C. Robertson8 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

1Hospital de São José, Dept. of Urology, Lisbon, Portugal, 2Klinika LFUK School of Medicine, Dept. of Urology, Bratislava, Slovakia, 3Jessenius School of Medecine, Dept. of Urology, Martin, Slovakia, 4St.James Univ. Hosp., Dept. of Urology, Leeds, United Kingdom, 5Amalia Fleming Hospital-, Dept. of Urology, Athens, Greece, 6Amalia Fleming Hospital, Dept. of Urology, Athens, Greece, 7Ankara Univ. Medical Ibni Siha, Dept. of Urology, Ankara, Turkey, 8Univ. of Strathclyde -, Dept. of Statistics, Glasgow, United Kingdom

Written by Reza Mehrazin, MD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe